SERENTIS
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.
SERENTIS
Industry:
Biopharma Health Care Medical Pharmaceutical
Founded:
2006-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.serentis-pharma.com
Total Employee:
11+
Status:
Active
Total Funding:
30.54 M USD
Technology used in webpage:
Nginx Baidu Analytics Peg Technic
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2007-10-02 | Surface Therapeutics Ltd. | Surface Therapeutics Ltd. acquired by Serentis | N/A |
Investors List
Apposite Capital
Apposite Capital investment in Series A - Serentis
East Hill Advisors
East Hill Advisors investment in Series A - Serentis
MVM Life Science Partners
MVM Life Science Partners investment in Series A - Serentis
Novo Holdings
Novo Holdings investment in Series A - Serentis
Novo Holdings
Novo Holdings investment in Series A - Serentis
Apposite Capital
Apposite Capital investment in Series A - Serentis
MVM Life Science Partners
MVM Life Science Partners investment in Series A - Serentis
Official Site Inspections
http://www.serentis-pharma.com
Unable to get host informations!!!
More informations about "Serentis"
Serentis - Crunchbase Company Profile & Funding
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and …See details»
Serentis Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Serentis Ltd. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 1 news, Drug:SRD-326, SRD-285, SRD-502, STP-04, STP-01b.See details»
Serentis Ltd. - LinkedIn
Serentis is a commercially focused, emerging biopharmaceutical company with a number of products in clinical trials. We operate an outsourcing model and have an established network …See details»
Serentis Ltd. - Overview, News & Similar companies - ZoomInfo
Serentis Ltd. contact info: Phone number: +44 1223437064 Website: www.serentis-pharma.com What does Serentis Ltd. do? Serentis is a commercially focused, emerging biopharmaceutical …See details»
Serentis Ltd. - Company Profile & Staff Directory - ContactOut
Serentis is a commercially focused, emerging biopharmaceutical company with a number of products in clinical trials. We operate an outsourcing model and have an established network …See details»
Serentis Ltd. Overview | SignalHire Company Profile
Serentis is a commercially focused, emerging biopharmaceutical company with a number of products in clinical trials. We operate an outsourcing model and have an established network …See details»
Serentis - Products, Competitors, Financials, Employees, …
Jul 1, 2016 Serentis is a biopharmaceutical company which aims to develop a pipeline of products to address unmet medical needs in the dermatology field. Use the CB Insights …See details»
Serentis Ltd. Financial Overview, Employee Count, and Competitors
Serentis is a commercially focused, emerging biopharmaceutical company with a number of products in clinical trials. We operate an outsourcing model and have an established network …See details»
Serentis Ltd - Company Profile and News - Bloomberg Markets
Serentis Ltd. provides biopharmaceutical services. The Company offers research and development of medical products and drugs for chemical modification and reformulations.See details»
Serentis - Crunchbase
Serentis develops medical products and drugs.See details»
Serentis - CoBee Company Profile & Funding Rounds
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and …See details»
Serentis - Contacts, Employees, Board Members, Advisors & Alumni
Serentis develops medical products and drugs.See details»
Serentis Ltd. | Insights
Jun 21, 2010 Latest on Serentis Ltd. Already A Biomedtracker Subscriber? You have access to the full company record through your subscription. Go To Biomedtracker. ... a Norstella …See details»
Serentis - Company Profile - Tracxn
Oct 20, 2024 Serentis ranks 287th among 287 competitors. 68 of its competitors are funded while 66 have exited. Overall, Serentis and its competitors have raised over $4.46B in funding …See details»
Serentis Ltd.:Company Profile & Technical Research,Competitor …
Serentis Ltd. is a company that provides Botanical drug, Herb and more. Serentis Ltd. is headquartered in United Kingdom . Serentis Ltd. was founded in 2006.See details»
Emerging Drug Developers: Serentis - Fierce Biotech
When Tim Sharpington looks across the landscape of biotechnology, it’s easy for him to find examples of the kind of company he’d most like to emulate. The UK’sSee details»
Emerging Drug Developer: Serentis - Fierce Biotech
Aug 24, 2007 Emerging Drug Developer: Serentis. By admin Aug 24, ... where Big Pharma companies wait and watch for the kind of promising therapies that can be snapped up and …See details»
Former Arakis Officials Raise $20.8M For New Firm Serentis
Jul 5, 2007 Co-founders of Serentis in addition to Sharpington were Alan Rothaul, chief scientific officer, who was head of biological sciences at Arakis, and Andy Baxter, research and …See details»
SRD-441 - Drug Targets, Indications, Patents - Synapse - Patsnap
A pivotal in vivo bioequivalence study comparing two formulations of 21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone ointment, …See details»
Serentis raises L10.3 million in financing - The Pharma Letter
Jul 8, 2007 Serentis raises L10.3 million in financing. serentis, raises, l10, million, financing, cambridge, uk. Friday 15 November 2024. About. Contact. Login. VC & Investment. M&A. AI. …See details»